China Resources Pharmaceutical Group Limited (03320) has disclosed the interim financial results for its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., covering the first half of 2026. The subsidiary achieved total operating revenue of approximately 15.014 billion yuan, reflecting a modest year-on-year growth of 1.37%.

However, the net profit attributable to shareholders of the listed parent company stood at around 1.671 billion yuan, marking a decline of 7.96% compared to the same period last year. Basic earnings per share were reported at 1 yuan.

In terms of shareholder returns, the board has proposed a cash dividend distribution of 4.15 yuan (inclusive of tax) for every 10 shares held, maintaining a payout commitment despite the softer profit performance.

The results underscore a challenging operating environment where top-line growth was achieved but bottom-line profitability faced pressure, highlighting cost or margin headwinds during the period.